Atai Beckley’s Lilly Deal Brings a Cash-and-Milestone Payout — Along with a Storm of Analyst Downgrades
Published on 07/21/2026 at 06:02 | Redaktion boerse-global.de
The euphoria that sent Atai Beckley shares rocketing after Eli Lilly’s $3.8 billion takeover proposal has quickly given way to a more measured, and at times skeptical, reality. The stock closed Monday at €6.25, slipping 0.79% from the prior session, even as it remains just a few percent below the 52-week high of €7.85 reached on the day of the announcement. That initial surge — a near-40% weekly gain fueled by the biggest single-day jump in the company’s history — has now attracted a wave of analyst downgrades and the scrutiny of several law firms.
The deal, unveiled on 16 July 2026, marks Eli Lilly’s entry into the psychedelic therapeutics space. Shareholders will receive $6.75 in cash per share, representing roughly $2.8 billion in equity value, plus contingent value rights (CVRs) worth up to an additional $2.50 per share. Those CVRs are tied to development and regulatory milestones for Atai Beckley’s two lead programs, giving the proposal a maximum potential value of about $3.8 billion. The transaction is expected to close by the end of September 2026.
At the heart of Lilly’s interest is BPL-003, an intranasal spray containing synthetic 5-MeO-DMT that is currently in Phase 3 studies for treatment-resistant depression. The FDA has awarded it Breakthrough Therapy designation. Phase 2b data showed patients experienced rapid and sustained improvement in depressive symptoms, with an average hospital discharge time of 100 minutes and a single dose’s effect lasting up to three months. Early Phase 3 results are anticipated in early 2029. Additional pipeline assets include VLS-01, a DMT-based oral dissolving film in Phase 2, and EMP-01, an MDMA-based therapy for social anxiety disorder that has already demonstrated efficacy and safety in a Phase 2a trial.
Despite the magnitude of the bid, analysts have been quick to downgrade the stock now that the acquisition price sets a ceiling on potential upside. On Monday, H.C. Wainwright’s Patrick Trucchio cut Atai Beckley from “Buy” to “Neutral” and slashed his price target to $7.50 from $25. Berenberg followed suit, downgrading to “Hold” with a $7.45 target. They join a long list of banks that pulled back in the prior week, including TD Cowen, Jefferies, Jones Research, Canaccord, Guggenheim, Maxim, Cantor Fitzgerald, and Needham. The rationale is uniform: once a takeover price is fixed, analysts no longer assess standalone growth prospects but instead focus solely on deal completion probability.
Should investors sell immediately? Or is it worth buying Atai Beckley?
Not everyone views the deal as negative for the sector. Jones Research pointed to positive read-throughs for other psychedelic therapy developers such as Compass Pathways, HelusPharma, Definium Therapeutics, and GH Research, arguing that Lilly’s willingness to pay a premium for a clinical-stage player could lift sentiment across the space. Cathie Wood of ARK Invest called the acquisition a “well-deserved” reward for shareholders and a validation of the vision for psychedelic medicine.
Meanwhile, several plaintiff law firms have launched investigations into whether Atai Beckley’s board fulfilled its fiduciary duties during the sale process. Ademi LLP, Brodsky & Smith, and Kahn Swick & Foti are each examining whether the $6.75 cash-and-CVR package adequately reflects the company’s intrinsic value. One probe specifically highlights a clause in the merger agreement that imposes a significant penalty if the board accepts a competing bid, effectively restricting rival offers. While such investigations are routine in large deals and do not guarantee the transaction will be blocked, they introduce a layer of uncertainty that merger-arbitrage investors are already pricing in.
Important stakeholders have already signaled their approval. Apeiron Investment Group and related parties, which together held 56.8 million shares — equivalent to 15.4% of voting rights as of 22 June 2026 — have entered into a voting agreement to support the merger. This backing provides a solid base for shareholder approval, though the outcome remains subject to the regulatory green light, the shareholder vote, and the results of the fiduciary-duty inquiries.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
With the stock now trading closer to the sum of the cash bid and CVR value than to its pre-deal fundamentals, the immediate price action appears less tied to clinical catalysts and more to the procedural timeline. The 14-day relative strength index sits at 75, signaling deeply overbought conditions after the recent rally. In the weeks ahead, Atai Beckley’s share price will likely dance to the rhythm of antitrust reviews, shareholder meetings, and legal filings — milestones that carry no breakthrough therapy designation but will determine whether investors ever collect their CVRs.
Ad
Atai Beckley Stock: New Analysis - 21 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
